2017 Annual Meeting
(500c) Accelerating Pharmaceutical Development through Precompetitive Collaboration: The Enabling Technologies Consortium
Authors
Joshua D. Engstrom - Presenter, Bristol-Myers Squibb Company
Srinivas Tummala - Presenter, Bristol-Myers Squibb
Jean W. Tom, Bristol-Myers Squibb
Margaret Faul, Amgen
The Enabling Technologies Consortium (ETC), which originated as a Working Group within the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium), is a consortium of pharmaceutical and biotech companies focused on the optimization of technologies that enable pharmaceutical development. The goal of ETC is to simplify and accelerate the process for establishing collaborations by standardizing the procedures and agreements under which they operate; to proactively identify high-value opportunities to deliver innovative technologies where the business case is compelling and collaboration with the broader external community (vendor, academic, government) is required. The current scope of the ETC is in technology within the Chemistry, Manufacturing and Controls (CMC) of drug substance development. This presentation provides an update on the progress of the overall âEnabling Technologiesâ effort since its inception in August 2015 using the drug substance drying working group as a case study